Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 0

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)

Registration No. 333-281489

PROSPECTUS

<div align='center'>4,349,010,000 Ordinary Shares Representing 434,901 American Depositary Shares

___________________</div>

This prospectus relates to
the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 4,349,010,000 ordinary
shares, nominal value £0.00005 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, or the Company, represented by 434,901
American Depositary Shares, or Depositary Shares, consisting of (1) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares,
issuable upon the exercise of Series J warrants, or Series J Warrants, issued in a July 2024 private placement, or the July 2024 Private
Placement, (2) 2,131,880,000 Ordinary Shares represented by 213,188 Depositary Shares, issuable upon the exercise of Series K warrants,
or Series K Warrants, issued in the July 2024 Private Placement, and (3) 85,250,000 Ordinary Shares represented by 8,525 Depositary Shares,
issuable upon the exercise of placement agent warrants, or the July 2024 Placement Agent Warrants, issued in the July 2024 Private Placement.

The selling shareholders are
identified in the table commencing on page 65. Each Depositary Share represents 10,000 Ordinary Shares. No Depositary Shares are being
registered hereunder for sale by us. We will not receive any proceeds from the sale of the Depositary Shares by the selling shareholders.
All net proceeds from the sale of the Ordinary Shares represented by Depositary Shares covered by this prospectus will go to the selling
shareholders. However, we may receive proceeds from any exercise of warrants held by selling shareholders. See “Use of Proceeds.”

The selling shareholders may
sell all or a portion of the Ordinary Shares represented by Depositary Shares from time to time in market transactions through any market
on which our Depositary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined
by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal
or by a combination of such methods of sale. See “